PCNA and Hepatic fibrosis: Gallic acid exhibited the ability to inhibit HSCs cell proliferation in a dose-dependent and time-dependent manner, decrease α-SMA expression, lower the levels of liver injury markers such as PCNA, PDGF-BB, TIMP-1, HP, and reduce collagen deposition in a rat model of liver fibrosis.